Targets › RHBDF2
1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Feb 2028.
Regulates ADAM17 protease, a sheddase of the epidermal growth factor (EGF) receptor ligands and TNF, thereby plays a role in sleep, cell survival, proliferation, migration and inflammation. Does not exhibit any protease activity on its own. (UniProt, Q6PJF5)
Open in Phaseline: the race on RHBDF2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| SciRhom | SR-878 iRhom2 (RHBDF2) inhibitor | RHBDF2 | Phase 1 | Rheumatoid Arthritis | Feb 2028 |
Rheumatoid Arthritis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.